JAMA

Analysis Group Researchers Evaluated Long-Term Patient Experience with Dupilumab Using Groundbreaking Method for Generating Real-World Data

Retrieved on: 
Tuesday, December 12, 2023
Regeneron Pharmaceuticals, JAMA Dermatology, Analysis Group, Atopic dermatitis, LEAP, Physician, Gold, Pros, Clinical trial, Yale school, RWD, Sinusitis, Harvard Medical School, Polyp (medicine), Yale School of Medicine, Area studies, JAMA, Nursing, Pharmaceutical industry, Sanofi, Dermatology, Patient

The study, published in the journal Dermatology and Therapy , extends the one-year results of the previously published RELIEVE-AD study in JAMA Dermatology , which was based on a groundbreaking method for generating real-world data (RWD).

Key Points: 
  • The study, published in the journal Dermatology and Therapy , extends the one-year results of the previously published RELIEVE-AD study in JAMA Dermatology , which was based on a groundbreaking method for generating real-world data (RWD).
  • This approach provides a true baseline against which to compare longitudinal data over time.
  • "Generating real-world data is particularly challenging for conditions like atopic dermatitis that require long-term therapy extending beyond the initial study period.
  • "Leveraging manufacturers' programs, such as patient support programs, has proven to be a breakthrough solution for generating early and long-term high-quality RWD."

Physician Leaders Ramin Davidoff, MD, and Maria Ansari, MD, FACC, co-CEOs of The Permanente Federation, Named Among Modern Healthcare's "100 Most Influential People" for 2023

Retrieved on: 
Wednesday, December 6, 2023
Kaiser Permanente, Data, DRS, Health equity, Research, Natural language processing, Cervical cancer, Nursing, Colorectal cancer, FACC, Hospital, Risk, Modern Healthcare, Breast cancer, Patient, Machine learning, Neoplasm, Workflow, American Medical Group Association, Computer, Davidoff, Home, Communication, Environment, Cancer, Physician, Diabetes, AI, JAMA, Blood pressure, Medical device, Management, MD

OAKLAND, Calif., Dec. 6, 2023 /PRNewswire/ -- The Permanente Federation today announced that Ramin Davidoff, MD, and Maria Ansari, MD, FACC, co-CEOs of The Permanente Federation, have been recognized by Modern Healthcare as among the "100 Most Influential People in Healthcare" for 2023.

Key Points: 
  • Dr. Davidoff serves as executive medical director and chair of the board of the Southern California Permanente Medical Group (SCPMG).
  • SCPMG consists of more than 8,100 physicians caring for more than 4.8 million Kaiser Permanente members.
  • He is also chair of the board and CEO of The Southeast Permanente Medical Group and chair of the board and CEO of the Hawaii Permanente Medical Group .
  • Dr. Ansari is also CEO and executive director of The Permanente Medical Group and president and CEO of Mid-Atlantic Permanente Medical Group .

$100M Saved in Drug Costs… And Growing

Retrieved on: 
Wednesday, November 29, 2023
EHR, ROI, Doctor of Pharmacy, Pharmacist, UCSF, Patient, Pharmacy, Growth, Blue Shield, Prescription, Health care, Workflow, MD, Partnership, JAMA, Nursing, Pharmaceutical industry, Gemini

SAUSALITO, Calif., Nov. 29, 2023 /PRNewswire/ -- Gemini Health LLC, a California-based drug cost transparency platform company, announced today that it has surpassed $100M in drug cost savings in partnership with major health plans. The savings were generated over the past three years by identifying and delivering lower cost, high-quality drug and pharmacy alternatives for roughly half of all prescriptions - ten times the industry average. Alternatives and related savings are then sent to prescribers and pharmacists in workflow, as well as to members, via five patented Gemini services. Savings are identified in actual claims and are calculated based upon switches from higher cost drugs and pharmacies to lower cost alternatives that occur after a Gemini alternative was presented.

Key Points: 
  • SAUSALITO, Calif., Nov. 29, 2023 /PRNewswire/ -- Gemini Health LLC, a California-based drug cost transparency platform company, announced today that it has surpassed $100M in drug cost savings in partnership with major health plans.
  • The savings were generated over the past three years by identifying and delivering lower cost, high-quality drug and pharmacy alternatives for roughly half of all prescriptions - ten times the industry average.
  • Alternatives and related savings are then sent to prescribers and pharmacists in workflow, as well as to members, via five patented Gemini services.
  • The Business Group on Health recently released its annual survey of large employers, naming drug costs as a top concern.

Houston Housing Authority Partners with Cardiac Solutions to Pioneer Life-Saving Initiative: Install AEDs in All Public Housing Complexes

Retrieved on: 
Wednesday, November 22, 2023
Sentinel, Houston Housing Authority, Safety, HHA, Cardiac arrest, LUCAS, AED, Journal, JAMA, American Medical Association, Public housing, CPR, Partnership, Survival, Death, Housing, Commissioner, AED (non-profit), Defibrillation, SCA, Medical device

HOUSTON, Nov. 22, 2023 /PRNewswire/ -- The Houston Housing Authority (HHA) and Cardiac Solutions have partnered to achieve a groundbreaking milestone by becoming the first housing agency in North America to install Automated External Defibrillators (AEDs) with LUCAS compression devices and AED Sentinel camera remote monitoring for all AEDs in all of its public housing complexes.

Key Points: 
  • HOUSTON, Nov. 22, 2023 /PRNewswire/ -- The Houston Housing Authority (HHA) and Cardiac Solutions have partnered to achieve a groundbreaking milestone by becoming the first housing agency in North America to install Automated External Defibrillators (AEDs) with LUCAS compression devices and AED Sentinel camera remote monitoring for all AEDs in all of its public housing complexes.
  • SCA occurs approximately once every 34 seconds in the United States, making it imperative to have life-saving equipment readily available in public spaces.
  • "By installing AEDs in all our public housing complexes, we are empowering our communities and enhancing our emergency response capabilities to save lives."
  • Jon Seale, CEO of Cardiac Solutions, expressed his support for the HHA's initiative: "The Houston Housing Authority's commitment to safety and readiness is commendable.

Full-Day Preschool Improves 3rd Grade School Achievement

Retrieved on: 
Sunday, November 19, 2023
Online, PARCC, JAMA Pediatrics, Pediatrics, CPC, University, Bill, Assessment, Multimedia, School, Ready-to-Learn, Driver CPC, Chicago Public Schools, JAMA, Tutoring, Online shopping, Nursing

MINNEAPOLIS, Nov. 19, 2023 /PRNewswire-PRWeb/ --

Key Points: 
  • Three- and four-year-olds participating in full-day preschool in the Child-Parent Center Education Program performed significantly better than their part-day counterparts in 3rd grade reading and math achievement.
  • [email protected]
    Children who attended a full-day preschool program in the Chicago Public School District had higher scores in 3rd grade reading and math achievement as well as reduced grade retention compared to children who attended part-day preschool, according to a study in the November 20 issue of JAMA.
  • Participation in high-quality preschool programs by age 4 has a long history of enhancing school readiness skills and promoting later school success and economic well-being.
  • Citation: Reynolds AJ, Smerillo NE, Ou SR, Loveman-Brown M, Varshney N. School performance in third grade after a full-day vs part-day preschool program.

Don Hardison Appointed Chairman of the Board at Geneoscopy

Retrieved on: 
Thursday, November 9, 2023
Biometrics, Biotechnology, Oncology, General Health, Health, Health Technology, Genetics, Other Health, Exact sciences, Food, RNA, Colorectal cancer, JAMA, Acquisition, PMA, Regulation of tobacco by the U.S. Food and Drug Administration, Growth, CRC, Labcorp, Quest Diagnostics, GSK plc, Hologic, Management

Geneoscopy , a life sciences company focused on developing diagnostic tests for gastrointestinal health, has appointed Don Hardison as Chairman of its Board of Directors.

Key Points: 
  • Geneoscopy , a life sciences company focused on developing diagnostic tests for gastrointestinal health, has appointed Don Hardison as Chairman of its Board of Directors.
  • Having previously served as a strategic advisor to Geneoscopy before joining the board in February 2023, Hardison is well-acquainted with the company's vision and strategy.
  • In his expanded role as Chairman of the Board, he will provide insight and guidance as Geneoscopy prepares to commercialize its flagship product – ColoSense™, a noninvasive, stool-based, at-home screening test designed to detect colorectal cancer and advanced adenomas in average-risk individuals.
  • "As an advisor and board member, I have been impressed by what Geneoscopy has accomplished, and I'm honored to assume the role of Chairman of the Board at Geneoscopy during this exciting inflection point for the company," said Hardison.

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Retrieved on: 
Wednesday, November 8, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Survival, VEGF, TAK, RAS, PDUFA, Food, Colorectal Cancer Alliance, MAA, Priority, JAMA, European Medicines Agency, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Medicines and Healthcare products Regulatory Agency, Priority review, PMDA, Colorectal cancer, CRC, EMA, FACP, Cancer, Metastasis, Patient, Diagnosis, Vanderbilt University Medical Center, Pharmaceutical industry, Takeda, EU, Lancet

"There is a pressing need for new treatments for individuals with metastatic colorectal cancer, who have had limited options and continue to face poor outcomes.

Key Points: 
  • "There is a pressing need for new treatments for individuals with metastatic colorectal cancer, who have had limited options and continue to face poor outcomes.
  • “For far too long, healthcare providers and patients have had limited options when selecting a therapy for metastatic colorectal cancer.
  • The trials investigated FRUZAQLA plus best supportive care versus placebo plus best supportive care in patients with previously treated mCRC.
  • “Colorectal cancer is a highly heterogeneous disease, making it difficult to bring advancements to patients whose cancer has metastasized.

Otsuka Medical Devices and Recor Medical Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension

Retrieved on: 
Wednesday, November 8, 2023
Medical Devices, FDA, Health, Clinical Trials, General Health, Cardiology, JAMA, ReCore, Food, Physician, Blood pressure, American Medical Association, News, Medical device, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Journal, Hypertension, Overactive bladder, RDN, Patient, Pharmaceutical industry

Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) and Recor Medical, Inc. (“Recor”, subsidiary of Otsuka Medical Devices) announced the U.S. Food and Drug Administration (FDA) has approved Recor’s Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension.

Key Points: 
  • Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) and Recor Medical, Inc. (“Recor”, subsidiary of Otsuka Medical Devices) announced the U.S. Food and Drug Administration (FDA) has approved Recor’s Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension.
  • The Paradise system is intended as an adjunctive treatment option when lifestyle changes and medications have not adequately controlled a patient’s blood pressure.
  • It is a first-of-its-kind ultrasound-based RDN technology designed to lower blood pressure by denervating the sympathetic nerves surrounding the renal arteries, reducing the overactivity that can lead to hypertension.
  • The Paradise system delivers two to three doses of 360-degree ultrasound energy — lasting seven seconds each — through each of the main renal arteries to the surrounding nerves.

Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension

Retrieved on: 
Wednesday, November 8, 2023
Biotechnology, FDA, Medical Devices, Health, Cardiology, JAMA, ReCore, Harvard Medical School, Food, American Medical Association, Blood pressure, Physician, Mortality, MD, Disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Journal, Hypertension, Division, Overactive bladder, Diabetes, RDN, Patient, Associate, Pharmaceutical industry, Endocrinology, Medicine, Brigham

Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced the U.S. Food and Drug Administration (FDA) has approved Recor’s Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension.

Key Points: 
  • Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced the U.S. Food and Drug Administration (FDA) has approved Recor’s Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension.
  • The Paradise system is intended as an adjunctive treatment option when lifestyle changes and medications have not adequately controlled a patient’s blood pressure.
  • The Paradise system delivers two to three doses of 360-degree ultrasound energy — lasting seven seconds each — through each of the main renal arteries to the surrounding nerves.
  • The Paradise Ultrasound RDN system previously received CE mark and has been successfully introduced in Europe and is an investigational device in Japan.

Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension

Retrieved on: 
Wednesday, November 8, 2023
JAMA, FDA, Harvard Medical School, Brigham and Women's Hospital, Food, American Medical Association, Blood pressure, Physician, Mortality, MD, Disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Journal, Hypertension, Division, Treatments for overactive bladder, Diabetes, RDN, Patient, Hospital, Associate, Pharmaceutical industry, ReCore, Endocrinology, Medicine

PALO ALTO, Calif., Nov. 8, 2023 /PRNewswire/ -- Recor Medical, Inc. ("Recor") and its parent company, Otsuka Medical Devices Co., Ltd. ("Otsuka Medical Devices") today announced the U.S. Food and Drug Administration (FDA) has approved Recor's Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension.

Key Points: 
  • Approval of the Paradise™ Ultrasound Renal Denervation system makes innovative hypertension treatment available for the first time in the U.S.
    PALO ALTO, Calif., Nov. 8, 2023 /PRNewswire/ -- Recor Medical, Inc. ("Recor") and its parent company, Otsuka Medical Devices Co., Ltd. ("Otsuka Medical Devices") today announced the U.S. Food and Drug Administration (FDA) has approved Recor's Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension.
  • The Paradise system is intended as an adjunctive treatment option when lifestyle changes and medications have not adequately controlled a patient's blood pressure.
  • The Paradise catheter features the exclusive HydroCooling™ system, which circulates sterile water through the balloon catheter during the procedure to help protect the renal artery wall.
  • Recor has been focused on developing and testing the Paradise Ultrasound RDN system for the treatment of hypertension since 2009.